Company VYNE Therapeutics Inc.

VYNE

US92941V3087

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for VYNE Therapeutics Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2023-11-27 pm EST			5-day change	1st Jan Change
3.970 ^USD	-1.00%		+0.51%	+47.04%

Nov. 13	Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q3 Revenue $114,000	MT
Nov. 13	VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. Its FMX114 is investigational combination gel formulation of tofacitinib and fingolimod that is designed to address both the source and cause of inflammation in atopic dermatitis (AD). The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans.

Number of employees : 12

Managers	Title	Age	Since
David Domzalski CEO	Chief Executive Officer	57	2020
Tyler Zeronda DFI	Director of Finance/CFO	37	-
Iain Stuart CTO	Chief Tech/Sci/R&D Officer	50	2020
Mutya Harsch LAW	General Counsel	49	2020

Members of the board	Title	Age	Since
Pat LePore BRD	Director/Board Member	68	2020
Steven Basta BRD	Director/Board Member	58	2014
Anthony D. Bruno BRD	Director/Board Member	67	2020
Elisabeth Sandoval BRD	Director/Board Member	61	2019
David Domzalski CEO	Chief Executive Officer	57	2020
Sharon Barbari BRD	Director/Board Member	69	2020

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	13,957,324	12,732,759 ( 91.23 %)	0	91.23 %

Name	Equities	%	Valuation
Cormorant Asset Management LP 9.990 %	1,394,336	9.990 %	4 M $
Eventide Asset Management LLC 9.990 %	1,394,336	9.990 %	4 M $
Citadel Advisors LLC 8.462 %	1,181,088	8.462 %	4 M $
Access Industries, Inc. (New York) 8.000 %	1,116,585	8.000 %	3 M $
Soleus Capital Management LP (Investment Management) 6.383 %	890,868	6.383 %	3 M $
DSC Advisors LP 0.8239 %	115,000	0.8239 %	350 750 $
The Vanguard Group, Inc. 0.3217 %	44,895	0.3217 %	136 930 $
Pat LePore 0.2613 %	36,472	0.2613 %	111 240 $
David Domzalski 0.2399 %	33,488	0.2399 %	102 138 $
Renaissance Technologies LLC 0.1861 %	25,976	0.1861 %	79 227 $

VYNE Therapeutics, Inc.

520 US Highway 22 Suite 204

08807, Bridgewater

http://www.vynetherapeutics.com

Trading Rating :

Investor Rating :

ESG Refinitiv :

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.970USD

Average target price

5.583USD

Spread / Average Target

+40.64%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi. (M$)
VYNE THERAPEUTICS INC.	+47.04%	55 M $
ELI LILLY AND COMPANY	+61.69%	532 B $
NOVO NORDISK A/S	+47.31%	464 B $
JOHNSON & JOHNSON	-14.36%	364 B $
ABBVIE INC.	-13.93%	246 B $
ROCHE HOLDING AG	-19.31%	216 B $
NOVARTIS AG	+2.31%	201 B $
ASTRAZENECA PLC	-11.78%	195 B $
PFIZER, INC.	-41.18%	170 B $
AMGEN INC.	+0.62%	141 B $

Other Pharmaceuticals